The EMPA-REG OUTCOME trial recorded that patients with T2DM and AF may especially benefit from the use of empagliflozin [114] and SGLT2i were associated with a lower risk of new-onset AF in T2DM patients compared to the dipeptidyl peptidase-4 inhibitor [115]. This evidence concerns the gene DPP4 and atrial fibrillation.